J&J beats first-quarter profit estimates

Sales of psoriasis drug Stelara were flat at $2.45 billion in the first quarter. Sales of blood cancer therapy Darzalex jumped about 19% to $2.69 billion. J&J has struck deals to delay U.S. launches of close-copy versions of Stelar until 2025.

J&J cell therapy is now approved for an earlier line of treatment than a competing drug from Bristol Myers. Meanwhile, Mount Sinai’s approach to AI is being looked at by Mount Sinai's approach to the treatment of AI patients in the U.S. Meanwhile, a look at the challenges posed by Bristol Myers' rival, Bristol's cell therapy.